Structured robotic gait training with the Trexo walker

Clinical Impacts of Structured Robotic Gait Training Programs

NA · University of Calgary · NCT07405450

This study will test whether a structured Trexo robotic gait training program helps people with neuromotor walking impairments (for example children with cerebral palsy or those with traumatic brain injury) improve walking and reach their therapy goals.

Quick facts

PhaseNA
Study typeInterventional
Enrollment120 (estimated)
SexAll
SponsorUniversity of Calgary (other)
Locations1 site (Calgary, Alberta)
Trial IDNCT07405450 on ClinicalTrials.gov

What this trial studies

The program enrolls people with neuromotor walking impairments who can fit and tolerate the Trexo robotic gait trainer and asks them to follow a structured, hospital-based training schedule. Participants complete repeated overground gait-training sessions with the Trexo device while researchers track adherence, safety, and progress toward patient, family, and therapist goals. Outcome measures include feasibility (attendance and adherence), functional walking measures, and goal attainment assessed at baseline and after the training period. The study also documents practical barriers to access to inform potential home- or community-based implementation.

Who should consider this trial

Good fit: Ideal candidates are people of any age with neuromotor walking impairments who can physically fit the Trexo device (about 5 ft 6 in or shorter and under ~150 lb), tolerate standing and repetitive gait training, and comply with study assessments and sessions.

Not a fit: Patients with contraindications to Trexo use—such as recent lower-extremity immobilization or weight-bearing restrictions, unstable cardiac or other medical conditions limiting activity, painful or symptomatic hypotension when standing, severe contractures that prevent forward movement, or those too large for the device—are unlikely to benefit from this program.

Why it matters

Potential benefit: If successful, the program could expand practical access to robotic walking therapy and help participants improve walking function and meet meaningful therapy goals.

How similar studies have performed: Prior small studies of robotic gait trainers have reported functional benefits for some participants, but results vary and broader effectiveness is limited by access and study heterogeneity.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* able to fit into Trexo robotic gait trainer (both leg length and weight); height of \<\~5'6", weight \<150 lbs.)
* able to fulfill training requirements throughout training period
* able to comply with study procedures (assessments, training)
* any age

Exclusion Criteria:

* those with contraindications to training with a robotic gait trainer (ie. medical condition or recent surgery requiring lower extremity immobilization or weight-bearing restriction (ie. fracture, unstable hip subluxation), medical condition requiring a physical activity restriction (ie. unstable arrythmia), pain or symptomatic hypotension while standing, contracture such that the Trexo Robotic Gait Training does not result in forward movement)
* those involved in a potentially confounding intervention (will be discussed case-by-case to determine risk of impacting the study results).

Where this trial is running

Calgary, Alberta

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Neuromotor Impairments, Walking Impairment, Robotic Walking, Trexo

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.